Brain Tumor - Pipeline Assessment and Market Forecasts to 2017


#41880

59pages

GlobalData

$ 2000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Brain tumor- Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global BRAIN TUMORmarket. The report identifies the key trends shaping and driving the global brain tumor market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain tumor sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimated the global brain tumor market to be at $914m in 2009, and forecasts it to grow at 11% annually for the next seven years to reach $2.1 billion by 2017. More novel therapies are expected to launch and this factor acts as a major driver for the market. The current market has three products approved for the treatment of brain tumors and there is a high opportunity for the pipeline products to enter into this potential market. 

Scope

The report provides information on the key drivers and challenges of the brain tumor market. Its scope includes:

  • Annualized global brain tumor market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as DNA replication inhibitor, VGEF inhibitor, Tyrodine Kinase inhibitor and Toposiomerase inhibitor.
  • Analysis of the current and future competition in the global brain tumor market. Key market players covered are Antisense Pharma, Pfizer, EMD Sereno, AstraZeneca, Bristol-myers Squibbs, Amgen.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the brain tumor therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global brain tumor market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global brain tumor market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global brain tumor market landscape? - Identify, understand and capitalize.
Table of Content

1 Table of contents 2

1.1 List of Tables 4
1.2 List of Figures 4

2 Disease Overview 5
2.1 Marketed Drugs 7
2.2 GlobalData Pipeline Report Guidance 8

3 Brain Tumor Therapeutics: Market Characterization 9
3.1 Brain Tumor Market Size 9
3.2 Brain Tumor Market Forecast and CAGR 9
3.3 Drivers and Barriers for Brain Tumor Market 11
3.3.1 Drivers for Brain Tumor Market 11
3.3.2 Barriers for Brain Tumor Market 11
3.4 Opportunity and Unmet Need 12
3.5 Key Takeaway 13

4 Brain Tumor Therapeutics: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profiles for Major Marketed Products in the Brain Tumor Market 15
4.3.1 Temodar 15
4.3.2 Avastin 16
4.3.3 Gliadel 17
4.4 Major Marketed Products Comparison in Brain Tumor Market 18
4.5 Key Takeaway 18

5 Brain Tumor Therapeutics: Pipeline Assessment 19
5.1 Overview 19
5.2 Strategic Pipeline Assessment 19
5.2.1 Technology Trends Analytic Framework 19
5.3 Brain Tumor Therapeutics - Promising Drugs under Clinical Development 21
5.4 Molecule Profile for Promising Drugs Under Clinical Development 22
5.4.1 Cilengitide 22
5.4.2 Trabedersen 23
5.4.3 Neuradiab 24
5.5 Brain Tumor Therapeutics Market Clinical Pipeline by Mechanism of Action 25
5.6 Brain Tumor Pipeline Pipeline by Clinical Phases of Development 26
5.6.1 Brain Tumor Therapeutics Regulatory and Phase III Clinical Pipeline 27
5.6.2 Brain Tumor Therapeutics Phase II Clinical Pipeline 28
5.6.3 Brain Tumor Therapeutics Phase I Clinical Pipeline 30
5.6.4 Brain Tumor Therapeutics Preclinical Pipeline 32
5.7 Key Takeaway 32

6 Brain Tumor Therapeutics: Implications for Future Market Competition 33

7 Brain Tumor Therapeutics: Future Players in the Brain Tumor Market 34

7.1 Introduction 34
7.2 AstraZeneca 34
7.2.1 Company Overview 34
7.2.2 Business Description 35
7.3 Antisense Pharma 37
7.3.1 Company Overview 37
7.4 EMD Serono, Inc. 38
7.4.1 Company Overview 38
7.5 GlaxoSmithKline plc. 38
7.5.1 Company Overview 38
7.5.2 Business Description 39
7.6 Bristol-Myers Squibb 42
7.6.1 Company Overview 42
7.6.2 Business Description 42
7.7 Pfizer Inc. 44
7.7.1 Company Overview 44
7.7.2 Business Description 44
7.8 F. Hoffmann-La Roche Ltd (Roche) 48
7.8.1 Company Overview 48
7.9 Novartis AG 50
7.9.1 Company Overview 50
7.9.2 Business Description 50

8 Brain Tumor Therapeutics: Appendix 54
8.1 Definitions 54
8.2 Acronyms 54
8.3 Research Methodology 54
8.3.1 Coverage 54
8.3.2 Secondary Research 55
8.3.3 Forecasting 55
8.3.4 Primary Research 58
8.3.5 Expert Panel Validation 58
8.4 Contact Us 58
8.5 Disclaimer 58
8.6 Sources 59
Table 1: The WHO grading of Brain Tumor 5
Table 2: Types of gliomas 5
Table 3: Types of tumors 6
Table 4: Marketed Drugs Description 7
Table 5: Brain Tumor Therapeutics, Global, Market Revenues ($bn), 20012009 9
Table 6: Brain Tumor Therapeutics, Global, Market Revenues ($bn), 20092017 10
Table 7: Major Marketed Products Comparison in Brain Tumor Market, 2010 18
Table 8: Brain Tumor Therapeutics Most Promising Drugs Under Clinical Development, 2010 21
Table 9: Brain Tumor Therapeutics Phase III Clinical Pipeline, 2010 27
Table 10: Brain Tumor Therapeutics Phase II Clinical Pipeline, 2010 28
Table 11: Brain Tumor Therapeutics Phase I Clinical Pipeline, 2010 30
Table 12: Brain Tumor Therapeutics Preclinical Clinical Pipeline, 2010 32
Table 13: AstraZeneca Oncology Pipeline Products 36
Table 14: AstraZeneca Brain Tumor Pipeline Products 37
Table 15: Antisense Pharma Oncology Pipeline Products 37
Table 16: GlaxoSmithKline plc. Oncology Pipeline Products 41
Table 17: GlaxoSmithKline plc. Brain Tumor Pipeline Products 41
Table 18: Bristol-Myers Squibb Company Oncology Pipeline Products, 2010 43
Table 19: Bristol-Myers Squibb Company Brain Tumor Pipeline Products, 2009 43
Table 20: Pfizer Inc Oncology Pipeline Products, 2010 46
Table 21: Pfizer Inc Brain Tumor Pipeline Products, 2010 47
Table 22: F. Hoffmann-La Roche Ltd. Oncology Pipeline Products, 2010 49
Table 23: F. Hoffmann-La Roche Ltd. Brain Tumor Pipeline Products 50
Table 24: Novartis AG Oncology Pipeline Products, 2010 52
Table 25: Novartis AG Brain Tumor Pipeline Products,2010 53
Figure 1: Distribution of incidence of CNS neoplasm based on the Central Brain Tumor Registry of the US 6
Figure 2: Treatment Options for Brain Tumor 7
Figure 3: Brain Tumor Therapeutics, Global, Market Revenues ($bn), 20012009 9
Figure 4: Brain Tumor Therapeutics, Global, Market Forecast, ($bn) 20092017 10
Figure 5: Opportunity and Unmet Need in the Brain Tumor Therapeutics Market 12
Figure 6: Strategic Competitor Assessment, 2009 14
Figure 7: Technology Trends Analytic Framework of the Brain Tumor Pipeline, 2010 19
Figure 8: Technology Trends Analytic Framework of the Brain Tumor Pipeline Description, 2010 20
Figure 9: Brain Tumor Therapeutics Pipeline by Mechanism of Action, 2010 25
Figure 10: Brain Tumor Pipeline by Phase of Development, 2010 26
Figure 11: Implications for Future Market Competition in the Brain Tumor Market, 2010 33
Figure 12: Brain Tumor TherapeuticsPipeline by Company , 2010 34
Figure 13: GlobalData Market Forecasting Model 57